Physician profile
Stephen A Morris
NPI 1598740979
$4,659.25
in general payments reported to CMS, 2019-2025
17 companies · $49.46 in 2025
The $49.46 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,179 · 2020: $1,560 · 2021: $425 · 2022: $260 · 2023: $62.32 · 2024: $124 · 2025: $49.46.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $173 · Entertainment: $62.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $172.96 |
| Entertainment | $62.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $2,400.00 | 2019-2020 | |
| Coopervision INC. | $379.85 | 2019-2022 | |
| Johnson & Johnson Vision Care, INC. | $280.79 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $243.42 | 2020-2021 | |
| Optos, INC. | $195.63 | 2019-2023 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Allergan, INC. | $191.94 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $124.99 | 2021 | |
| Shire North American Group INC | $124.76 | 2019 | |
| Bausch & Lomb Americas INC. | $123.50 | 2024 | Xiidra, Miebo |
| Genzyme Corporation | $121.60 | 2022 | |
| Maculogix, INC. | $114.61 | 2020 | |
| Genentech USA, INC. | $90.23 | 2020 | |
| Visioneering Technologies, INC. | $81.54 | 2019 | |
| Alcon Vision LLC | $59.15 | 2019-2022 | |
| Abb Con-Cise Optical Group LLC | $50.00 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $49.46 | 2025 | Xdemvy |
| Glaukos Corporation | $27.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Morris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.